Source comparison
BPC-157 Ulcer Healing Complete Guide 2026: Comparison
Before drawing conclusions from any single study, understanding how BPC-157 compares to standard treatments clarifies where the evidence is strong and where it's speculative. BPC-157 (research peptide) VEGF upregulation, eNOS activation, mucosal cytoprotection
This comparison does not assign a generated winner or score.
- Before drawing conclusions from any single study, understanding how BPC-157 compares to standard treatments clarifies where the evidence is strong and where it's speculative.
- BPC-157 (research peptide)
- VEGF upregulation, eNOS activation, mucosal cytoprotection
- Pre-clinical only (rodent models, no human RCTs)
- 7–14 days in animal models (60–80% ulcer area reduction)
- Not FDA-approved; no human safety data; synthesis purity varies
- Proton pump inhibitors (omeprazole, pantoprazole)
- Irreversible H+/K+ ATPase inhibition. Reduces gastric acid secretion by 90%+
- Phase III RCTs, FDA-approved
- 4–8 weeks for complete healing in 85–95% of patients
- Rebound hyperacidity on discontinuation; long-term use linked to B12 deficiency
- H2-receptor antagonists (ranitidine, famotidine)
- Competitive inhibition of histamine H2 receptors. Reduces acid secretion by 60–70%
- 6–12 weeks for healing in 70–85% of patients
- Less potent than PPIs; tolerance develops with prolonged use
- Sucralfate
- Forms protective barrier over ulcer site; binds bile acids and pepsin
- 4–8 weeks for healing in 75–85% of patients
- Requires acidic environment to activate; less effective if taken with PPIs